Eikon Therapeutics, Inc. disclosure shows Innovation Endeavors reporting persons collectively beneficially owned 3,369,519 shares of common stock, representing 6.2% of outstanding shares as of March 31, 2026.
The holdings break down as IE III LP2,723,226 shares, IE IV LP498,474 shares, and IE ET SPV147,819 shares. The filing states shared voting and dispositive power over these holdings and cites 54,138,555 shares outstanding as of March 17, 2026 from the company’s Form 10-K.
Positive
None.
Negative
None.
Insights
Innovation Endeavors holds a modest, non-controlling stake in Eikon Therapeutics.
The filing discloses an aggregate position of 3,369,519 shares (6.2%) across three affiliated limited partnerships and their general partners, with shared voting and dispositive authority noted for each partnership’s GP.
Because the statement is a Schedule 13G-style passive ownership disclosure and the Reporting Persons disclaim group status, the position should be viewed as a passive institutional stake; any material change would require an updated filing.
Shared voting authority is concentrated through general partners rather than sole control.
The filing attributes voting and investment authority to the general partners (IE III GP, IE IV GP, IE ET GP) over the underlying LP holdings; each GP reports shared voting/dispositive power rather than sole power.
This structure implies decision-making flows through the GP entities; subsequent corporate actions or coordination among affiliated funds would be disclosed in future Schedule filings if voting alignment changes.
Key Figures
Aggregate shares held:3,369,519 sharesIE III LP holdings:2,723,226 sharesIE IV LP holdings:498,474 shares+3 more
6 metrics
Aggregate shares held3,369,519 sharesAggregate beneficial ownership as of March 31, 2026
IE III LP holdings2,723,226 sharesDirectly held by IE III LP as of March 31, 2026
IE IV LP holdings498,474 sharesDirectly held by IE IV LP as of March 31, 2026
IE ET SPV holdings147,819 sharesDirectly held by IE ET SPV as of March 31, 2026
Percent of class6.2%Collective percent based on 54,138,555 shares outstanding as of March 17, 2026
Shares outstanding used54,138,555 sharesShares outstanding as of March 17, 2026 (Form 10-K citation)
Key Terms
Schedule 13G, beneficially owned, shared dispositive power, disclaim status as a 'group'
4 terms
Schedule 13Gregulatory
"Row 9 of each Reporting Person's cover page to this sets forth the aggregate number"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially ownedfinancial
"The Reporting Persons' ownership of the Issuer's securities consists of (i) 2,723,226 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powergovernance
"Shared Dispositive Power 2,723,226.00"
disclaim status as a 'group'legal
"The Reporting Persons expressly disclaim status as a "group" for purposes of this ."
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Eikon Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
282564103
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Innovation Endeavors III LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,723,226.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,723,226.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,723,226.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Innovation Endeavors III GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,723,226.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,723,226.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,723,226.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Innovation Endeavors IV LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
498,474.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
498,474.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
498,474.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Innovation Endeavors IV GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
498,474.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
498,474.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
498,474.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.9 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Innovation Endeavors ET SPV LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
147,819.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
147,819.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
147,819.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
282564103
1
Names of Reporting Persons
Innovation Endeavors ET SPV GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
147,819.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
147,819.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
147,819.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Eikon Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
230 Harriet Tubman Way, Millbrae, CA, 94030.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
Innovation Endeavors III LP ("IE III LP")
Innovation Endeavors III GP, LLC ("IE III GP")
Innovation Endeavors IV LP ("IE IV LP")
Innovation Endeavors IV GP, LLC ("IE IV GP")
Innovation Endeavors ET SPV LP ("IE ET SPV")
Innovation Endeavors ET SPV GP LLC ("IE ET GP")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
1845 El Camino Real, Palo Alto, CA 94306
(c)
Citizenship:
IE III LP Cayman Islands
IE III GP Cayman Islands
IE IV LP Delaware
IE IV GP Delaware
IE ET SPV Delaware
IE ET GP Delaware
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
282564103
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
The Reporting Persons' ownership of the Issuer's securities consists of (i) 2,723,226 shares of common stock directly held by IE III LP; (ii) 498,474 shares of common stock directly held by IE IV LP; and (iii) 147,819 shares of common stock directly held by IE ET SPV.
IE III GP is the general partner of IE III LP and shares voting and investment authority over the shares held by IE III LP.
IE IV GP is the general partner of IE IV LP and shares voting and investment authority over the shares held by IE IV LP.
IE ET GP is the general partner of IE ET SPV and shares voting and investment authority over the shares held by IE ET SPV.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 54,138,555 shares of common stock outstanding as of March 17, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 30, 2026. Collectively, the Reporting Persons beneficially owned an aggregate of 6.2% of the outstanding common stock of the Issuer as of March 31, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Innovation Endeavors III LP
Signature:
/s/ Dror Berman
Name/Title:
By Innovation Endeavors III GP, LLC, its General Partner, By Dror Berman, Managing Member
Date:
05/15/2026
Innovation Endeavors III GP, LLC
Signature:
/s/ Dror Berman
Name/Title:
By Dror Berman, Managing Member
Date:
05/15/2026
Innovation Endeavors IV LP
Signature:
/s/ Dror Berman
Name/Title:
By Innovation Endeavors IV GP, LLC, its General Partner, By Dror Berman, Managing Member
Date:
05/15/2026
Innovation Endeavors IV GP, LLC
Signature:
/s/ Dror Berman
Name/Title:
By Dror Berman, Managing Member
Date:
05/15/2026
Innovation Endeavors ET SPV LP
Signature:
/s/ Dror Berman
Name/Title:
By Innovation Endeavors ET SPV GP LLC, its General Partner, By Dror Berman, Managing Member
What stake does Innovation Endeavors hold in EIKN?
Innovation Endeavors entities collectively beneficially owned 3,369,519 shares, representing 6.2% of Eikon Therapeutics’ common stock as of March 31, 2026. The position is disclosed across three affiliated limited partnerships and their general partners.
How are the Innovation Endeavors holdings allocated by entity?
The filing lists IE III LP: 2,723,226 shares, IE IV LP: 498,474 shares, and IE ET SPV: 147,819 shares, each shown with shared voting and dispositive power through their respective general partners as of March 31, 2026.
What voting or dispositive power do the Reporting Persons report?
Each Reporting Person reports 0 sole voting and sole dispositive power and reports shared voting and dispositive power over the listed shares; general partners (IE III GP, IE IV GP, IE ET GP) share voting and investment authority over the underlying LP holdings.
What outstanding share base does the filing use to calculate percentage ownership?
The percentages are calculated using 54,138,555 shares outstanding as of March 17, 2026, cited from Eikon Therapeutics’ Annual Report on Form 10-K filed March 30, 2026, which the filing incorporates by reference.
Does the filing indicate active group coordination among Reporting Persons?
The Reporting Persons explicitly disclaim status as a 'group' for purposes of the filing. The statement therefore presents affiliated holdings but does not assert coordinated group action in this disclosure.
